Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients

Breast Cancer: Basic and Clinical Research

Volumn 5, Issue 1, 2011, Pages

  Qi, Ji Ping ^a   Yang, You Lin ^a   Zhu, Hong ^a   Wang, Jianmin ^c   Jia, Ying ^a   Liu, Na ^a   Song, Yue Jia ^a   Zan, Li Kun ^a   Zhang, Xu ^a   Zhou, Min ^a   Gu, Yun He ^a   Liu, Tao ^a   Hicks, David G ^b   Tang, Ping ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

Author keywords

Androgen receptor; Breast cancer; Estrogen receptor; HER2; Ki 67; Molecular classifcation; Progesterone receptor

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CHINESE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 83755174700     PISSN: 11782234     EISSN: None     Source Type: Journal    
DOI: 10.4137/BCBCR.S8323     Document Type: Article

References (42)

1. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980-91.
2. Goldhirch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1318-29.
3. Colbleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastasis breast cancer that has progressed after chemotherapy for metastasis disease. J Clin Oncol. 1999; 17:2639-48.
4. Lumachi F, Luisetto G, Basso SM, et al. Endocirne therapy of breast cancer. Curr Med Chem. 2011;18:513-22.
5. Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity of title of convenience? Nat Rev Clin Oncol. 2010;7:683-92.
6. Lachapelle J, Foulkes WD. Triple-negative and basal-like breast cancer: implications for oncologists. Curr Oncol. 2011;18:161-4.
7. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas. Potential relevance to new therapeutic strategies. Cancer. 2003;98:703-11.
8. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Am J Clin Pathol. 2003;120:725-31.
9. Hanley K, Wang J, Bourne P, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high grade ductal carcinoma of the breast. Hum Pathol. 2008;39:386-92.
10. Pristauz G, Petru E, Stacher E, et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations. Histopathology. 2010;57:877-84.
11. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2006;109:25-32.
12. Schippinger W, Regitnig P, Dandachi N, et al. Evaluation of the prognostic signifcance of androgen receptor expression in metastatic breast cancer. Virchows Arch. 2006;449:24-30.
13. Hardin C, Pommier R, Calhoun K, et al. A new hormonal therapy for estrogen receptor-negative breast cancer. World J Surg. 2007;31:1041-6.
14. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol. 2008;4:15-21.
15. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
16. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-74.
17. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-23.
18. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-74.
19. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-71.
20. Cheang MCU, Chia SK, Voduc D, et al. KI67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101:736-50.
21. Bhargara R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer. 2010;116:1431-9.
22. Bharagava R, Dabbs DJ. Luminal B breast tumors are not HER2 positive. Breast Cancer Res. 2008;10:404-5.
23. World Health Organization Classifcation of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Editors. Tavassoli FA and Devilee P. Lyon: IARC Press, 2003.
24. Moe RE, Anderson BO. Androgen and androgen receptors: a clinical neglected sector in breast cancer biology. J Surg Oncol. 2006;95:437-9.
25. Suzuki T, Miki Y, Takagi K, et al. Androgens in human breast carcinoma. Med Mol Morphol. 2010;43:75-81.
26. Gonzalez LO, Corte MD, Vazquez J, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer. 2008;8:149.
27. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast Cancer. Ann Oncol. 2010;21:488-92.
28. Agrawal AK, Jelen M, Grzebieniak Z, et al. Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochem Cytobiol. 2008;46:269-76.
29. Hammond E, Hayes DF, Dowsett M, et al. American Society of clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-95.
30. Ogawa Y, Hai E, Matsumoto K, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008;13:431-5.
31. Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010; 23:205-12.
32. Ibrahim M, Dodson A, Barnett S, et al. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2). Am J Clin Pathol. 2008;129:398-09.
33. Collins L, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the nurses' health study. Mod Pathol. advance online publication: doi: 2011;10:1038.
34. Micello D, Marando A, Sahnane N, et al. Androgen receptor is frequently expressed in HER2-positive ER/PR-negative breast cancers. Virchows Arch. 2010;457:467-76.
35. Subik K, Lee JF, Baxter L, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 2010;4:35-41.
36. Kollara A, Kahn HJ, Marks A, Brown TJ. Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res Treat. 2001;67:245-53.
37. Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011; 17:1867-74.
38. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010;16:62-5.
39. Macedo LF, Guo Z, Tilghman SL, et al. Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole. Cancer Res. 2006;66:7775-82.
40. Suzuki T, Miki Y, Akahira J, et al. Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations. Endocr J. 2008;55:455-63.
41. Calhoun KE, Pommier RF, Muller P, Fletcher WS, Toth-Fejel S. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. Arch Surg. 2003;138:879-83.
42. Toth-Fejel S, Cheek J, Calhoun K, Muller P, Pommier RF. Estrogen and androgen receptors as co-mediators of breast cancer cell proliferation. Providing a new therapeutic tool. Arch Surg. 2004;139:50-4.